z-logo
open-access-imgOpen Access
Progresszív kórlefolyást mutató szisztémás mastocytosis
Author(s) -
Judit Várkonyi,
Gergely Szombath,
Anna Vályi-Nagy,
Judit Csomor,
Krisztina Egedi,
Ilona Kovalszky,
Katalin Tölgyesi,
László Szerafin,
László Tóth,
Györgyi Soós,
Tamás Masszi
Publication year - 2018
Publication title -
orvosi hetilap
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.176
H-Index - 21
eISSN - 1788-6120
pISSN - 0030-6002
DOI - 10.1556/650.2018.30978
Subject(s) - medicine , systemic mastocytosis , cytopenia , tryptase , bone marrow , gastroenterology , pediatrics , surgery , mast cell , immunology
Authors report on a case of a male patient of systemic mastocytosis that was associated with extensive cutaneous lesions. Chronic diarrhoea worsening his quality of life was well managed by the administration of antihistamines. The pleural fluid recurrence soon after drainage has been controlled by the administration of alpha interferon. 40 years after the onset of the first skin signs progression has been manifested in the development of "B" (bone marrow infiltration rate >30%, dysmyelopoiesis, serum tryptase >20 μg/L, hepato- and splenomegaly) and "C" symptoms (liver function test abnormalities, cytopenia, malabsorption, osteoporosis). The patient died at age of 87. The authors' aim was to attract attention on this rare disease and emphasize that symptomatic therapy with antihistamines and drugs available based on customised rights by the National Health Insurance Fund might provide good quality of life. Orv Hetil. 2018; 159(5): 192-196.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom